Welcome to our dedicated page for Hutchmed (China) news (Ticker: HCM), a resource for investors and traders seeking the latest updates and insights on Hutchmed (China) stock.
HUTCHMED (China) Limited develops and commercializes targeted therapies and immunotherapies for cancer and immunological diseases through a China-based commercial organization and a global clinical pipeline. News for HCM centers on marketed oncology products such as FRUZAQLA and ELUNATE for fruquintinib, ORPATHYS for savolitinib, China regulatory actions, and partner-driven commercialization outside China.
Recurring updates also cover pipeline compounds including sovleplenib, HMPL-760 and HMPL-A580, clinical data presented at oncology meetings, and the company’s Antibody-Targeted Therapy Conjugate platform. Corporate items include annual results, product-license updates such as TAZVERIK in China, board and committee changes, and disclosures tied to HUTCHMED’s Nasdaq, AIM and HKEX listings and ADR structure.
Hutchison China MediTech Limited (Nasdaq/AIM: HCM) announced that CEO Mr. Christian Hogg will participate in a virtual fireside chat at the Bank of America 2020 Health Care Conference on May 14, 2020, at 9:40 a.m. EDT. The event will be streamed live and can be accessed via the company's website. Following this conference, Chi-Med's senior management will hold one-on-one meetings at several upcoming events, including the Citi Virtual Pan-Asia Regional Investor Conference and Jefferies Global Healthcare Conference. Chi-Med aims to advance its pipeline of cancer therapies.